Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Introduction: Alzheimer’s disease (AD) is increasing in frequency as the global population ages. Five drugs are approved for treatment of AD, including four cholinesterase inhibitors and an N -methyl-D-aspartate (NMDA)-receptor antagonist. We have an urgent need to find new therapies for AD. Methods: We examined Clinicaltrials.gov, a public website that records ongoing clinical trials. We examined the decade of 2002 to 2012, to better understand AD-drug development. We reviewed trials by sponsor, sites, drug mechanism of action, duration, number of patients required, and rate of success in terms of advancement from one phase to the next. We also reviewed the current AD therapy pipeline. Results: During the 2002 to 2012 observation period, 413 AD trials were performed: 124 Phase 1 trials, 206 Phase 2 trials, and 83 Phase 3 trials. Seventy-eight percent were sponsored by pharmaceutical companies. The United States of America (U.S.) remains the single world region with the greatest number of trials; cumulatively, more non-U.S. than U.S. trials are performed. The largest number of registered trials addressed symptomatic agents aimed at improving cognition (36.6%), followed by trials of disease-modifying small molecules (35.1%) and trials of disease-modifying immunotherapies (18%). The mean length of trials increases from Phase 2 to Phase 3, and the number of participants in trials increases between Phase 2 and Phase 3. Trials of disease-modifying agents are larger and longer than those for symptomatic agents. A very high attrition rate was found, with an overall success rate during the 2002 to 2012 period of 0.4% (99.6% failure). Conclusions: The Clinicaltrials.gov database demonstrates that relatively few clinical trials are undertaken for AD therapeutics, considering the magnitude of the problem. The success rate for advancing from one phase to another is low, and the number of compounds progressing to regulatory review is among the lowest found in any therapeutic area. The AD drug-development ecosystem requires support.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the very high failure rate of clinical trials of AD therapeutics (of ~99.6%), many of which were successful in preclinical testing using these animal models [6, 27, 139]”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“New AD drug development has faced many obstacles, including high monetary and time costs and high failure rates in preclinical and clinical trials (Cummings et al., 2014;Yiannopoulou et al., 2019).”
From Drug repurposing for Alzheimer’s disease from 2012–2022—a 10-year literature review (2023) · cites this paper as Cummings et al., 2014
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Currently approved drugs do little to limit disease progression, and no preventive therapies are available.3,4”
From AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease (2018) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“the success rate of drugs that have gone through clinical trials from 2002 to 2012 show a high failure rate (~ 99.6%) [69]”
From Microglia and monocytes in inflammatory CNS disease: integrating phenotype and function (2022) · cites this paper as [69]
The cited source says what the claim attributes to it.
In the citing paper
“Efforts to develop drugs to treat Alzheimer’s dementia (AD) have a >99% failure rate”
From Exposure to Air Pollution in Relation to Risk of Dementia and Related Outcomes: An Updated Systematic Review of the Epidemiological Literature (2021) · cites this paper as Cummings et al. 2014
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 1×
“This is among the lowest for any therapeutic area [13,14].”
Background2013 Alzheimer's disease facts and figures
Alzheimer's Association, Thies, W., & Bleiler, L. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.02.003 · Cited by 3,328
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536 · cited 1×
“This is among the lowest for any therapeutic area [13,14].”
BackgroundThe International Committee of Medical Journal Editors
van der Weyden, M. (2006) · Proceedings of the Workshop on Publishing for Biomedical Journal Editors and Reviewers · doi:10.2349/biij.2.4.e54-13 · Cited by 1,998
Monetary Costs of Dementia in the United States
Hurd, M. D., Martorell, P., Delavande, A., Mullen, K. J., & Langa, K. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmsa1204629 · Cited by 1,484 · cited 1×
“economy than cardiovascular disease or cancer [31].”
2012 Alzheimer's disease facts and figures Alzheimer's Association ∗
Thies, W., & Bleiler, L. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.02.001 · Cited by 982
Donepezil and memantine for moderate-to-severe Alzheimer's disease
Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106668 · Cited by 782 · cited 1×
“2014 receptor AD antagonist (memantine) [3,4].”
Alzheimer's Disease and the Amyloid Cascade Hypothesis: A Critical Review
Reitz, C. (2012) · International Journal of Alzheimer's Disease · doi:10.1155/2012/369808 · Cited by 376 · cited 1×
“neurobiology of AD, and use of combinations of therapies may provide new approaches to AD therapy [24-26].”
BackgroundMullane, K., & Williams, M. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.11.014 · Cited by 213 · cited 1×
“Many failures in AD drug development have occurred, with both small molecules and immunotherapies failing to show a drug/placebo difference or having unacceptable toxicity [5-8].”
Background
Research works printed but not linked: 4
- Food and Drug Administration: Guidance for Industry: Information Program on Clinical Trials for Serious or Life-threatening Disease and Conditions. 2002, Bethesda, MD: US Department of Health and Human Services, Food and Drug Administration
- Food and Drug Administration: Guidance for Industry: Information Program on Clinical Trials for Serious or Life-threatening Disease and Conditions. 2004, Bethesda: US Department of Health and Human Services, Food and Drug Administration
- Getz K, Lamberti MJ: 89% of trials meet enrollment, but timelines slip, half of sites under-enroll. Tufts Cent Study Drug Dev. 2013, 15: 1-4.
- DiMasi JA: Clinical success rates for new cancer drugs double while more enter testing. Tufts Center Study Drug Dev Impact Rep. 2013, 15: 1-4.
Cited by
Items 201–300 of 1,003
Mishra, C. B., Kumari, S., Manral, A., Prakash, A., Saini, V., Lynn, A. M., & Tiwari, M. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.09.057 · Cited by 107
Beckett, L. A., Donohue, M. C., Wang, C., Aisen, P., Harvey, D. J., Saito, N., & Initiative, A. D. N. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.05.004 · Cited by 105
“All r ments have limited efficacy, and many clinical trials have failed to demonstrate any clinical impact [2,3].”
BackgroundNeurodegeneration: From cellular concepts to clinical applications
Katsnelson, A., De Strooper, B., & Zoghbi, H. Y. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aal2074 · Cited by 106
Introducing Therioepistemology: the study of how knowledge is gained from animal research
Garner, J. P., Gaskill, B. N., Weber, E. M., Dallaire, J. A., & Pritchett‐Corning, K. R. (2017) · Lab Animal · doi:10.1038/laban.1224 · Cited by 115
Model organism development and evaluation for late‐onset Alzheimer's disease: MODEL‐AD
Oblak, A. L., Forner, S., Territo, P. R., Sasner, M., Carter, G. W., Howell, G. R., Sukoff‐Rizzo, S. J., Logsdon, B. A., Mangravite, L. M., Mortazavi, A., et al. (2020) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12110 · Cited by 105
Albright, J., & Initiative, A. D. N. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.07.001 · Cited by 104
Cuadrado‐Tejedor, M., García, C., Sánchez-Arias, J. A., Rabal, O., Pérez-González, M., Mederos, S., Ugarte, A., Franco, R., Segura, V., Perea, G., et al. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.163 · Cited by 108
“The discouraging results of therapies for Alzheimer’s disease (AD) in clinical trials, 99.6% failure from 2002 to 2012 (Cummings et al, 2014), highlights the urgent need for new approaches to achieve effective therapy.”
BackgroundInfluentialVitek, M. P., Araujo, J. A., Fossel, M., Greenberg, B. D., Howell, G. R., Rizzo, S. J. S., Seyfried, N. T., Tenner, A. J., Territo, P. R., Windisch, M., et al. (2020) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12114 · Cited by 103
Cognitive training for people with mild to moderate dementia
Bahar‐Fuchs, A., Martyr, A., Goh, A., Sabatés, J., & Clare, L. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013069 · Cited by 111
Natural Compounds and Autophagy: Allies Against Neurodegeneration
Stacchiotti, A., & Corsetti, G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.555409 · Cited by 110
“…multifactorial pathogenesis of neurodegenerative diseases is clinically unsuccessful, traditional medicinal herbs or plants with beneficial pleiotropic effects may represent a plausible preventive auxiliary therapeutic opportunity (Cummings et al., 2014; Park et al., 2018; Di Paolo et al., 2019).”
BackgroundTari, A. R., Nauman, J., Zisko, N., Skjellegrind, H. K., Bosnes, I., Bergh, S., Stensvold, D., Selbæk, G., & Wisløff, U. (2019) · The Lancet Public Health · doi:10.1016/s2468-2667(19)30183-5 · Cited by 100
Paumier, A., Boisseau, S., Jacquier‐Sarlin, M. R., Pernet‐Gallay, K., Buisson, A., & Albrieux, M. (2021) · Brain · doi:10.1093/brain/awab281 · Cited by 118
The price of progress: Funding and financing Alzheimer's disease drug development
Cummings, J., Reiber, C., & Kumar, P. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.04.008 · Cited by 98
“The failure rate of AD drug development is 99% [8]; the failure rate of the development of disease-modifying therapies for AD is 100%.”
BackgroundSelf-citationYue, X., Nguyen, T. D., Zellmer, V., Zhang, S., & Zorlutuna, P. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.04.001 · Cited by 97
Accelerating stem cell trials for Alzheimer's disease
Hunsberger, J. G., Rao, M., Kurtzberg, J., Bulte, J. W. M., Atala, A., LaFerla, F. M., Greely, H. T., Sawa, A., Gandy, S., Schneider, L. S., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00332-4 · Cited by 97
Chalfont, G., Milligan, C., & Simpson, J. (2020) · Dementia · doi:10.1177/1471301218795289 · Cited by 97
Genetic variants in Alzheimer disease — molecular and brain network approaches
Gaiteri, C., Mostafavi, S., Honey, C. J., De Jager, P. L., & Bennett, D. A. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.84 · Cited by 96
Gamberger, D., Lavrač, N., Srivatsa, S., Tanzi, R. E., & Doraiswamy, P. M. (2017) · Scientific Reports · doi:10.1038/s41598-017-06624-y · Cited by 95
Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing
Fang, J., Pieper, A. A., Nussinov, R., Lee, G., Bekris, L., Leverenz, J. B., Cummings, J., & Cheng, F. (2020) · Medicinal Research Reviews · doi:10.1002/med.21709 · Cited by 94
“6%.(9,10) 146 investigational drug candidates in clinical trials have been halted due to safety and efficacy concerns (Figure 1A) in the past two decades (1998–2017).”
BackgroundSelf-citationLarsson, S. C., & Markus, H. S. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-180288 · Cited by 94
“Recent clinical trials in AD, many based on the amyloid hypothesis, have been disappointing [4] and this has increased interest in other potential therapeutic avenues.”
Hossain, M. S., & Hussain, M. H. (2025) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70131 · Cited by 121
“From 2002 to 2012, only one out of 244 tested compounds for AD has gained FDA approval, corresponding to a success rate of merely 0.4% [18].”
InfluentialThe Ubiquitin-Proteasome System and Molecular Chaperone Deregulation in Alzheimer’s Disease
Sulistio, Y. A., & Heese, K. (2015) · Molecular Neurobiology · doi:10.1007/s12035-014-9063-4 · Cited by 98
Lemes, L. F. N., Ramos, G. D. A., de Oliveira, A. S., da Silva, F. M. R., Couto, G. C., Boni, M. S., Guimarães, M. J. R., Souza, I. N. D. O., Bartolini, M., Andrisano, V., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.12.024 · Cited by 100
Pisani, L., Farina, R., Catto, M., Iacobazzi, R. M., Nicolotti, O., Cellamare, S., Mangiatordi, G. F., Denora, N., Soto‐Otero, R., Siragusa, L., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00562 · Cited by 94
Brandt, J., Buchholz, A., Henry-Barron, B., Vizthum, D., Avramopoulos, D., & Cervenka, M. C. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-180995 · Cited by 93
The Microbiota-Gut-Brain Axis in Health and Disease and Its Implications for Translational Research
Schächtle, M., & Rosshart, S. P. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.698172 · Cited by 105
“…resulted in animals displaying several neurological problems (Sudo et al., 2004; Neufeld et al., 2011; Clarke et al., 2013; De Vadder et al., 2014; Daneman and Prat, 2015; Buffington et al., 2016) like impaired social behaviors (Cryan and Dinan, 2012; Buffington et al., 2016), reduced anxiety…”
BackgroundVojtechova, I., Machacek, T., Kristofikova, Z., Stuchlik, A., & Petrasek, T. (2022) · PLOS Pathogens · doi:10.1371/journal.ppat.1010929 · Cited by 92
Future Perspective of Diabetic Animal Models
Pandey, S., & Dvorakova, M. C. (2020) · Endocrine, Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530319666190626143832 · Cited by 89
Shin, J., Kong, C., Lee, J., Choi, B. Y., Sim, J., Koh, C. S., Park, M., Na, Y. C., Suh, S. W., Chang, W. S., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0569-x · Cited by 92
Donanemab for Alzheimer’s Disease: A Systematic Review of Clinical Trials
Rashad, A., Rasool, A., Shaheryar, M., Sarfraz, A., Sarfraz, Z., Robles-Velasco, K., & Cherrez-Ojeda, I. (2022) · Healthcare · doi:10.3390/healthcare11010032 · Cited by 91
Beltran, W. A., Cideciyan, A. V., Iwabe, S., Swider, M., Kosyk, M. S., McDaid, K., Martynyuk, I., Ying, G.-S., Shaffer, J., Deng, W.-T., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1509914112 · Cited by 89
“Proc Natl Acad Sci USA 110(6):E517–E525.”
BackgroundGerber, H., Wu, F., Dimitrov, M., Garcia Osuna, G. M., & Fraering, P. C. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.754101 · Cited by 89
“Consequently, different A and Tau-based therapeutic approaches are currently under clinical or preclinical studies for preventing or slowing down the progression of AD (3).”
BackgroundAyaz, M., Ullah, F., Sadiq, A., Kim, M. O., & Ali, T. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01417 · Cited by 89
The informed road map to prevention of Alzheimer Disease: a call to arms
McDade, E., Llibre-Guerra, J. J., Holtzman, D. M., Morris, J. C., & Bateman, R. J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00467-y · Cited by 89
Satlin, A., Wang, J., Logovinsky, V., Berry, S., Swanson, C., Dhadda, S., & Berry, D. A. (2016) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.01.001 · Cited by 89
Targeting microglia for the treatment of Alzheimer’s disease
McGeer, P. L., & McGeer, E. G. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.988707 · Cited by 88
Alzheimer’s disease – the journey of a healthy brain into organ failure
Golde, T. E. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00523-1 · Cited by 88
Epidemiology of Dementia: The Burden on Society, the Challenges for Research
Wolters, F. J., & Ikram, M. A. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7704-8_1 · Cited by 107
Neural stem cell therapy for neurovascular injury in Alzheimer's disease
Boese, A. C., Hamblin, M. H., & Lee, J.-P. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2019.113112 · Cited by 86
Cell models for Alzheimer’s and Parkinson’s disease: At the interface of biology and drug discovery
Cetin, S., Knez, D., Gobec, S., Kos, J., & Pišlar, A. H. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112924 · Cited by 107
Cespón, J., Miniussi, C., & Pellicciari, M. C. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.03.001 · Cited by 106
“Studies of changes in cognition and the brain related to ageing and cognitive decline and investigations into residual plasticity mechanisms in the brains of individuals at advanced stages of life are important research activities that will assist in the diversification of pharmacological targets (Cummings et al., 201…”
Metabolic Dysfunction in Alzheimer’s Disease: From Basic Neurobiology to Clinical Approaches
Clarke, J. R., Ribeiro, F. C., Frozza, R. L., De Felice, F. G., & Lourenco, M. V. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179911 · Cited by 87
“However, even therapies initially considered extremely promising have been found somewhat disappointing in clinical trials [12, 13].”
InfluentialStrong and reliable synaptic communication between pyramidal neurons in adult human cerebral cortex
Hunt, S., Leibner, Y., Mertens, E. J., Barros-Zulaica, N., Kanari, L., Heistek, T. S., Karnani, M., Aardse, R., Wilbers, R., Heyer, D. B., et al. (2022) · Cerebral Cortex · doi:10.1093/cercor/bhac246 · Cited by 89
Kim, M., Snowden, S., Suvitaival, T., Ali, A., Merkler, D. J., Ahmad, T., Westwood, S., Baird, A., Proitsi, P., Nevado‐Holgado, A., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.03.004 · Cited by 85
“trials in symptomatic patients, these have been unsuccessful in producing a reversal of symptoms or a slowing of the progression of the disease [6].”
BackgroundPrecision Nutrition for Alzheimer’s Prevention in ApoE4 Carriers
Norwitz, N. G., Saif, N., Ariza, I. E., & Isaacson, R. S. (2021) · Nutrients · doi:10.3390/nu13041362 · Cited by 85
Xu, J., Zhang, P., Huang, Y., Zhou, Y., Hou, Y., Bekris, L. M., Lathia, J., Chiang, C.-W., Li, L., Pieper, A. A., et al. (2021) · Genome Research · doi:10.1101/gr.272484.120 · Cited by 84
Self-citationColligris, P., de Lara, M. J. P., Colligris, B., & Pintor, J. J. (2018) · Journal of Ophthalmology · doi:10.1155/2018/8538573 · Cited by 93
“As of 2018, there is no modifying therapy for AD [15], and only two families of medications are approved as palliatives for AD symptoms: the cholinesterase inhibitors and the N-methyl-D-aspartate receptor (NMDAR) antagonists, while various new drugs are under clinical trials evaluations, among them the promising new f…”
BackgroundNanomaterials toward the treatment of Alzheimer’s disease: Recent advances and future trends
Zeng, H., Qi, Y., Zhang, Z., Liu, C., Peng, W., & Zhang, Y. (2021) · Chinese Chemical Letters · doi:10.1016/j.cclet.2021.01.014 · Cited by 83
The Kynurenine Pathway and Kynurenine 3-Monooxygenase Inhibitors
Hughes, T. D., Güner, O. F., Iradukunda, E. C., Phillips, R. S., & Bowen, J. P. (2022) · Molecules · doi:10.3390/molecules27010273 · Cited by 83
“Until now, pharmacologic treatments for AD have tried to control cognitive deficits through the administration of acetylcholinesterase inhibitors in an effort to increase acetylcholine levels in the CNS, but such strategies have only had modest success [80].”
BackgroundDrug Repositioning Approaches for the Discovery of New Therapeutics for Alzheimer's Disease
Kim, T. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0325-7 · Cited by 87
“4% during the period 2001–12) [6, 7].”
Benchmarking biopharmaceutical process development and manufacturing cost contributions to R&D
Farid, S. S., Baron, M., Stamatis, C., Nie, W., & Coffman, J. (2020) · mAbs · doi:10.1080/19420862.2020.1754999 · Cited by 81
“The worstcase scenario used an overall success rate of 4% derived from using the industrial average phase transition probabilities for pre-clinical to Phase II stages whilst addressing the possibility that for some therapeutic areas, such as Alzheimer’s disease, the phase transition probability of Phase III could be e…”
MethodBaird, D. A., Liu, J. Z., Zheng, J., Sieberts, S. K., Perumal, T., Elsworth, B., Richardson, T. G., Chen, C.-Y., Carrasquillo, M. M., Allen, M., et al. (2021) · PLOS Genetics · doi:10.1371/journal.pgen.1009224 · Cited by 83
Development of Multifunctional Pyrimidinylthiourea Derivatives as Potential Anti-Alzheimer Agents
Li, X., Wang, H., Lu, Z., Zheng, X., Ni, W., Zhu, J., Fu, Y., Lian, F., Zhang, N., Li, J., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00636 · Cited by 82
Preclinical Evaluation of18F-JNJ64349311, a Novel PET Tracer for Tau Imaging
Declercq, L., Rombouts, F., Koole, M., Fierens, K., Mariën, J., Langlois, X., Andrés, J. I., Schmidt, M., Macdonald, G., Moechars, D., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.185199 · Cited by 83
“timately failed in late-stage-development clinical trials (1).”
Worries About Getting Alzheimer’s: Who’s Concerned?
Cutler, S. J. (2015) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/1533317514568889 · Cited by 82
Hiremathad, A., Keri, R. S., Esteves, A. R., Cardoso, S. M., Chaves, S., & Santos, M. A. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.02.023 · Cited by 89
Active immunization therapies for Parkinson's disease and multiple system atrophy
Schneeberger, A., Tierney, L., & Mandler, M. (2015) · Movement Disorders · doi:10.1002/mds.26377 · Cited by 89
The Complex Role of Apolipoprotein E in Alzheimer’s Disease: an Overview and Update
Mahoney‐Sanchez, L., Belaidi, A. A., Bush, A. I., & Ayton, S. (2016) · Journal of Molecular Neuroscience · doi:10.1007/s12031-016-0839-z · Cited by 89
Metabolomics Analyses of Saliva Detect Novel Biomarkers of Alzheimer’s Disease
Huan, T., Tran, T., Zheng, J.-M., Sapkota, S., Macdonald, S., Camicioli, R., Dixon, R., & Li, L. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-180711 · Cited by 70
Ng, T. K. S., Fam, J., Feng, L., Cheah, I. K.-M., Tan, C. T.-Y., Nur, F., Wee, S. T., Goh, L. G., Chow, W. L., Ho, R., et al. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0696-y · Cited by 92
Alzheimer’s Disease Therapeutic Approaches
Revi, M. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-32633-3_15 · Cited by 101
Ambure, P. S., Bhat, J., Puzyn, T., & Roy, K. (2018) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2018.1456975 · Cited by 80
Sabbagh, M. N., Hendrix, S., & Harrison, J. E. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.11.004 · Cited by 80
Polygenic risk scores: An overview from bench to bedside for personalised medicine
Cross, B., Turner, R. M., & Pirmohamed, M. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1000667 · Cited by 98
Can exercise training teach us how to treat Alzheimer's disease?
Huuha, A. M., Norevik, C. S., Moreira, J. B. N., Kobro-Flatmoen, A., Scrimgeour, N., Kivipelto, M., Van Praag, H., Ziaei, M., Sando, S. B., Wisløff, U., et al. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101559 · Cited by 79
Toyonaga, T., Smith, L. M., Finnema, S. J., Gallezot, J.-D., Naganawa, M., Bini, J., Mulnix, T., Cai, Z., Ropchan, J., Huang, Y., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.223867 · Cited by 79
“There are no disease-modifying drugs approved for the treatment of AD (1).”
BackgroundGeerts, H., Dacks, P. A., Devanarayan, V., Haas, M., Khachaturian, Z. S., Gordon, M. F., Maudsley, S., Romero, K., Stephenson, D., & (BHMI), B. H. M. I. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.04.008 · Cited by 79
“6% of the clinical trials of diseasemodifying treatments for AD have failed [4].”
BackgroundPatassini, S., Begley, P., Xu, J., Church, S. J., Kureishy, N., Reid, S. J., Waldvogel, H. J., Faull, R. L. M., Snell, R. G., Unwin, R. D., et al. (2019) · Metabolites · doi:10.3390/metabo9060113 · Cited by 83
Rollins, C. P. E., Gallino, D., Kong, V., Ayranci, G., Devenyi, G. A., Germann, J., & Chakravarty, M. M. (2019) · NeuroImage: Clinical · doi:10.1016/j.nicl.2018.11.016 · Cited by 79
“…al., 2011; Ho et al., 2012), suggesting that obesity may accelerate the neurodegenerative trajectories towards AD by impacting critical brain areas that appear to be preferentially preserved in healthy aging (Tardif et al., 2018; Amaral et al., 2016; Voineskos et al., 2015; de Flores et al., 2015).”
BackgroundVoorhees, J. R., Remy, M. T., Cintrón-Pérez, C. J., El Rassi, E., Khan, M. Z., Dutca, L. M., Yin, T. C., McDaniel, L. N., Williams, N. S., Brat, D. J., et al. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.10.023 · Cited by 78
Yu, Y., Li, W., Mao, L., Peng, W., Long, D., Li, D., Zhou, R., & Dang, X. (2021) · Journal of Drug Targeting · doi:10.1080/1061186x.2021.1929257 · Cited by 78
Pistollato, F., Ohayon, E. L., Lam, A., Langley, G. R., Novak, T. J., Pamies, D., Perry, G., Trushina, E., Williams, R. S. B., Roher, A. E., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9175 · Cited by 77
Pharmacological Rescue of Long-Term Potentiation in Alzheimer Diseased Synapses
Prieto, G. A., Trieu, B. H., Dang, C. T., Bilousova, T., Gylys, K. H., Berchtold, N. C., Lynch, G., & Cotman, C. W. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.2774-16.2016 · Cited by 78
“Despite a worldwide effort to identify drugs that alleviate memory deficits, such as occur in AD, no effective treatments currently exist despite 400 clinical trials (Cummings et al., 2014).”
BackgroundInfluentialTravessa, A., Rodrigues, F. B., Mestre, T., & Ferreira, J. J. (2017) · Journal of Huntington s Disease · doi:10.3233/jhd-170245 · Cited by 85
“For example, 78% of clinical trials in Alzheimer’s disease are funded exclusively by industry [21].”
Advancing Alzheimer’s research: a review of big data promises
Zhang, R., Simon, G., & Yu, F. (2017) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2017.07.002 · Cited by 77
“Hence, it’s paramount to develop effective interventions to prevent AD from occurrence, slow down AD progression once it occurs, and improve quality of life and care for people and families who are affected by AD (3).”
BackgroundThe Global Economic Impact of Neurodegenerative Diseases: Opportunities and Challenges
Zahra, W., Nand, S., Birla, H., Singh, S. S., Dilnashin, H., Rathore, A. S., & Singh, S. P. (2019) · Springer eBooks · doi:10.1007/978-981-13-9431-7_17 · Cited by 113
Alzheimer’s/Vascular Spectrum Dementia: Classification in Addition to Diagnosis
Emrani, S., Lamar, M., Price, C. C., Wasserman, V., Matusz, E. F., Au, R., Swenson, R. A., Nagele, R. G., Heilman, K. M., & Libon, D. J. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190654 · Cited by 97
“The failure of clinical trials to treat AD has been attributable to patient-selection strategies [5].”
McGinley, L. M., Sims, E., Lunn, J. S., Kashlan, O. N., Chen, K. S., Bruno, E. S., Pacut, C. M., Hazel, T., Johe, K., Sakowski, S. A., et al. (2016) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0103 · Cited by 76
Remembering your A, B, C's: Alzheimer's disease and ABCA1
Lewandowski, C. T., Laham, M. S., & Thatcher, G. R. J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.01.011 · Cited by 76
2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease
Alzheimer's Association National Plan Milestone Workgroup, Fargo, K. N., Aisen, P., Albert, M., Au, R., Corrada, M. M., DeKosky, S., Drachman, D., Fillit, H., Gitlin, L., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.08.103 · Cited by 76
microRNAs as early biomarkers of Alzheimer’s disease: a synaptic perspective
Siedlecki-Wullich, D., Miñano-Molina, A. J., & Rodríguez-Álvarez, J. (2021) · Cells · doi:10.3390/cells10010113 · Cited by 76
“This fact added to the lack of accessible and reliable methods for detecting preclinical phases has probably led to the failure of potential therapies so far [11].”
Phase II clinical trials of anti–amyloid β antibodies: When is enough, enough?
Gold, M. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.04.005 · Cited by 75
“abysmal with no single Phase III trial reporting a positive result on a primary outcome [9].”
BackgroundWu, W., Dai, Y.-C., Li, N., Dong, Z., Gu, T., Shi, Z., Xue, X., Tang, Y., & Duan, J. (2017) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2016.1210139 · Cited by 80
“The results of the analysis published by Cumming et al.151 is advanced to the FDA and approved for marketing.”
ResultThe Role of Genetics in Advancing Precision Medicine for Alzheimer’s Disease—A Narrative Review
Freudenberg-Hua, Y., Li, W., & Davies, P. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00108 · Cited by 74
“This statement holds despite the stunning fact that between 2002 and 2014, more than 400 drug trials for AD have been performed but subsequently failed (129).”
BackgroundSchultz, L., Zurich, M., Culot, M., Costa, A. D., Landry, C., Bellwon, P., Kristl, T., Hörmann, K., Ruzek, S., Aiche, S., et al. (2015) · Toxicology in Vitro · doi:10.1016/j.tiv.2015.05.016 · Cited by 81
“Very high attrition rate (Kola and Landis, 2004) and too few compounds to begin with are the reason for inefficient drug development for neurodegenerative diseases, including Alzheimer’s disease (Cummings et al., 2014).”
Panes-Fernández, J., Wendt, A., Ramírez-Molina, O., Castro, P. A., & Fuentealba, J. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.317957 · Cited by 82
Mckean, N. E., Handley, R. R., & Snell, R. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313168 · Cited by 88
New Drugs from Marine Organisms in Alzheimer’s Disease
Russo, P., Kisialiou, A., Lamonaca, P., Moroni, R., Prinzi, G., & Fini, M. (2015) · Marine Drugs · doi:10.3390/md14010005 · Cited by 90
Calcium signalling: A common target in neurological disorders and neurogenesis
Glaser, T., Arnaud-Sampaio, V. F., Lameu, C., & Ulrich, H. (2018) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2018.12.002 · Cited by 79
Sun, Y., Huang, J., Chen, Y., Shang, H., Zhang, W., Yu, J., He, L., Xing, C., & Zhuang, C. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104172 · Cited by 73
The Use of Pigs as a Translational Model for Studying Neurodegenerative Diseases
Hoffe, B., & Holahan, M. R. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00838 · Cited by 83
Peng, B., Tong, Z., Tong, W. Y., Pasic, P. J., Oddo, A., Dai, Y., Luo, M., Frescene, J., Welch, N. G., Easton, C. D., et al. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c17102 · Cited by 81
Amyloid Cascade Hypothesis for the Treatment of Alzheimer’s Disease: Progress and Challenges
Wu, T., Lin, D., Cheng, Y., Jiang, S., Riaz, M. W., Fu, N., Mou, C., Ye, M., & Zheng, Y. (2022) · Aging and disease · doi:10.14336/ad.2022.0412 · Cited by 73
“However, the clinical trials of drugs targeting Aβ are challenging with a 99% failure rate [13-15].”
BackgroundChai, Y. L., Chong, J. R., Weng, J., Howlett, D., Halsey, A., Lee, J. H., Attems, J., Aarsland, D., Francis, P. T., Chen, C. P., et al. (2019) · Brain Pathology · doi:10.1111/bpa.12631 · Cited by 73
Anti-Tau Trials for Alzheimer's Disease: A Report from the EU/US/CTAD Task Force
Cummings, J., Blennow, K., Johnson, K., Keeley, M., Bateman, R. J., Molinuevo, J. L., Touchon, J., Aisen, P., & Vellas, B. (2019) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2019.14 · Cited by 71
Self-citationDo, H. T. T., & Cho, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176211 · Cited by 79
Sphingolipid-Enriched Extracellular Vesicles and Alzheimer’s Disease: A Decade of Research
Dinkins, M. B., Wang, G., & Bieberich, E. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-160567 · Cited by 72
“The current success rate in AD therapy is dismal (i.e., >99% failure rate of clinical trials in the last 10 years), and there are only five palliative FDA-approved drugs available, one NMDA receptor antagonist and four cholinesterase inhibitors [7].”
Korologou-Linden, R., Bhatta, L., Brumpton, B. M., Howe, L. D., Millard, L. A. C., Kolaric, K., Ben-Shlomo, Y., Williams, D. M., Smith, G. D., Anderson, E. L., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32183-6 · Cited by 71
Kenny, A., McArdle, H., Calero, M., Rabano, A., Madden, S. F., Adamson, K., Forster, R., Spain, E., Prehn, J. H. M., Henshall, D. C., et al. (2019) · SSRN Electronic Journal · doi:10.2139/ssrn.3429882 · Cited by 71
“Consequently, the focus has now shifted to implementing therapies at earlier stages of the disease offering a better opportunity for effective treatment and greater retention of cognitive function [8].”
BackgroundSnow, A. D., Castillo, G. M., Nguyen, B. P., Choi, P. Y., Cummings, J. A., Cam, J. A., Hu, Q., Lake, T. P., Pan, W., Kastin, A. J., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-38645-0 · Cited by 82
Self-citation
Metadata
- Authors
- Cummings, J. L., Morstorf, T., & Zhong, K.
- Affiliations
- Cleveland Clinic (US)
- Touro University Nevada (US)
- Corresponding author
- Cummings, Jeffrey L
- Venue
- Alzheimer's Research & Therapy
- Published
- 2014-07-03
- Volume
- 6
- Issue
- 4
- Pages
- 37-37
- ISSN
- 1758-9193 (ISSN-L)
- PMC
- PMC4095696
- OpenAlex
- W2146249493
- Cited by
- 1,744
- References
- 29
- Citations by year
- 2026: 86 · 2025: 65 · 2024: 113 · 2023: 122 · 2022: 189 · 2021: 193 · 2020: 208 · 2019: 207 · 2018: 200 · 2017: 144 · 2016: 122 · 2015: 79 · 2014: 15
- FWCI
- 79.49
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Alzheimer s Research & Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, drug development pipeline, clinical trials, trial attrition, disease-modifying therapy, immunotherapy, cholinesterase inhibitors, NMDA receptor antagonists, ClinicalTrials.gov, pharmaceutical industry sponsorship
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
